+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunoglobulin Product Market by Source (Pooled Human Plasma, Recombinant), Product Type (Hyperimmune Globulin, Standard Immunoglobulin), Route Of Administration, Application - Global Forecast 2025-2030- Product Image
Immunoglobulin Product Market by Source (Pooled Human Plasma, Recombinant), Product Type (Hyperimmune Globulin, Standard Immunoglobulin), Route Of Administration, Application - Global Forecast 2025-2030- Product Image
Sale

Immunoglobulin Product Market by Source (Pooled Human Plasma, Recombinant), Product Type (Hyperimmune Globulin, Standard Immunoglobulin), Route Of Administration, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904902
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immunoglobulin product market is evolving rapidly, driven by global advances in therapeutic applications, innovative technologies, and shifting regulatory landscapes. Senior healthcare stakeholders face mounting opportunities and challenges as the sector diversifies, adapts, and responds to changing clinical, operational, and policy conditions.

Market Snapshot: Immunoglobulin Product Market Growth & Outlook

The Immunoglobulin Product Market grew from USD 18.92 billion in 2024 to USD 21.39 billion in 2025. It is expected to continue growing at a CAGR of 12.66%, reaching USD 38.72 billion by 2030. Market expansion is underpinned by widening applications in immune-mediated diseases, enhanced manufacturing capabilities, and the growing need for effective therapies as the global burden of chronic and infectious illnesses rises.

Scope & Segmentation of the Immunoglobulin Product Market

  • Sources: Pooled Human Plasma, Recombinant
  • Product Types: Hyperimmune Globulin, Standard Immunoglobulin
  • Routes of Administration: Intramuscular, Intravenous, Subcutaneous
  • Clinical Applications: Hematological Disorders (Hemolytic Anemia, Idiopathic Thrombocytopenic Purpura), Infectious Diseases (Hepatitis A, Rubella, Varicella), Neurological Disorders (Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Myasthenia Gravis), Primary Immune Deficiency (Common Variable Immunodeficiency, Severe Combined Immunodeficiency, X-linked Agammaglobulinemia)
  • Geographical Coverage: Americas (United States—including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Technologies: Recombinant antibody engineering, digital health applications for monitoring, advanced purification, and filtration methods
  • Key Companies: CSL Behring, Grifols S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A., Biotest AG, LFB S.A., Bio Products Laboratory Limited, GC Pharma Co., Ltd., Shanghai RAAS Blood Products Co., Ltd.

Key Takeaways for Senior Decision-Makers

  • The immunoglobulin product market is transitioning from specialized treatments to standard care protocols across diverse clinical indications, prompting strategic shifts in manufacturing and distribution.
  • Technological innovation—including advancements in recombinant platforms and digital health integration—is increasing product differentiation and supporting more precise, patient-centric therapies.
  • Global demographic changes, such as rising rates of autoimmune and age-related diseases, are fueling sustained demand and compelling industry leaders to reevaluate capacity planning and portfolio strategies.
  • Regulatory frameworks are evolving, pushing manufacturers to adopt rigorous compliance systems for quality, traceability, and post-market monitoring throughout the value chain.
  • Collaboration among biotechnology startups, academic researchers, and established manufacturers is accelerating innovation cycles, reducing development timelines, and broadening therapeutic possibilities.
  • Regional nuances—ranging from plasma supply infrastructure in the Americas to regulatory diversity across EMEA and accelerated demand in Asia-Pacific—require tailored market entry and supply chain resilience strategies.

Tariff Impact: U.S. Trade Policy Effects on Supply Chain

Recent adjustments in United States tariff policy have increased operational costs for many global immunoglobulin suppliers, impacting the cost structure of imported materials, equipment, and finished therapies. This has catalyzed renewed investment in domestic plasma collection and encouraged companies to pursue alternative sourcing agreements and partnerships that safeguard against regulatory and economic volatility. Stakeholders are actively reassessing supplier and distribution strategies to mitigate risk.

Methodology & Data Sources Supporting Immunoglobulin Product Market Analysis

Comprehensive market insights are derived from primary interviews with key industry stakeholders, supply chain specialists, and senior executives, alongside secondary research from peer-reviewed publications, regulatory filings, and clinical trial data. Data triangulation and external advisor review strengthen analytical accuracy and minimize bias.

Why This Report Matters for Your Strategic Decisions

  • Empowers executives with actionable frameworks to address clinical, regulatory, and operational challenges unique to the immunoglobulin sector.
  • Supports strategic planning by detailing segmentation, technology adoption, regional market structures, and emerging partnership opportunities.
  • Enables risk mitigation through in-depth analysis of trade policy impacts and best-practice recommendations for resilient sourcing and innovation pipelines.

Conclusion

This report offers senior leaders a clear, actionable overview of evolving immunoglobulin product market dynamics and their implications for business growth. Leverage these insights to guide investment, operational adjustments, and cross-functional strategies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surge in development of recombinant monoclonal immunoglobulin therapies targeting autoimmune diseases
5.2. Integration of personalized immunoglobulin dosing algorithms using real-time immunomonitoring data in clinical practice
5.3. Expansion of plasma collection networks in emerging markets to secure immunoglobulin supply amid global shortages
5.4. Increasing focus on nanobody-based immunoglobulins for improved tissue penetration and stability in oncology indications
5.5. Advances in glycoengineering of immunoglobulin Fc regions to enhance antibody-dependent cellular cytotoxicity efficacy
5.6. Growth of pediatric subcutaneous immunoglobulin administration programs with wearable infusion devices for improved adherence
5.7. Collaboration between biotech firms and blood centers to optimize next generation Fc-fusion immunoglobulin production platforms
5.8. Regulatory approvals for novel immunoglobulin formulations with extended half-life to reduce infusion frequency for patients
5.9. Application of artificial intelligence for predictive forecasting of immunoglobulin demand and supply chain optimization
5.10. Strategic partnerships for regional immunoglobulin manufacturing to mitigate serum-derived product quality variability concerns
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immunoglobulin Product Market, by Source
8.1. Introduction
8.2. Pooled Human Plasma
8.3. Recombinant
9. Immunoglobulin Product Market, by Product Type
9.1. Introduction
9.2. Hyperimmune Globulin
9.3. Standard Immunoglobulin
10. Immunoglobulin Product Market, by Route Of Administration
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Immunoglobulin Product Market, by Application
11.1. Introduction
11.2. Hematological Disorders
11.2.1. Hemolytic Anemia
11.2.2. Idiopathic Thrombocytopenic Purpura
11.3. Infectious Diseases
11.3.1. Hepatitis A
11.3.2. Rubella
11.3.3. Varicella
11.4. Neurological Disorders
11.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
11.4.2. Guillain-Barre Syndrome
11.4.3. Myasthenia Gravis
11.5. Primary Immune Deficiency
11.5.1. Common Variable Immunodeficiency
11.5.2. Severe Combined Immunodeficiency
11.5.3. X-Linked Agammaglobulinemia
12. Americas Immunoglobulin Product Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Immunoglobulin Product Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Immunoglobulin Product Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. CSL Behring
15.3.2. Grifols, S.A.
15.3.3. Takeda Pharmaceutical Company Limited
15.3.4. Octapharma AG
15.3.5. Kedrion S.p.A.
15.3.6. Biotest AG
15.3.7. LFB S.A.
15.3.8. Bio Products Laboratory Limited
15.3.9. GC Pharma Co., Ltd.
15.3.10. Shanghai RAAS Blood Products Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. IMMUNOGLOBULIN PRODUCT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. IMMUNOGLOBULIN PRODUCT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. IMMUNOGLOBULIN PRODUCT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. IMMUNOGLOBULIN PRODUCT MARKET: RESEARCHAI
FIGURE 24. IMMUNOGLOBULIN PRODUCT MARKET: RESEARCHSTATISTICS
FIGURE 25. IMMUNOGLOBULIN PRODUCT MARKET: RESEARCHCONTACTS
FIGURE 26. IMMUNOGLOBULIN PRODUCT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IMMUNOGLOBULIN PRODUCT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY POOLED HUMAN PLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY POOLED HUMAN PLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STANDARD IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STANDARD IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMOLYTIC ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMOLYTIC ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEPATITIS A, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RUBELLA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY RUBELLA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY VARICELLA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY VARICELLA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COMMON VARIABLE IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COMMON VARIABLE IMMUNODEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SEVERE COMBINED IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SEVERE COMBINED IMMUNODEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY X-LINKED AGAMMAGLOBULINEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY X-LINKED AGAMMAGLOBULINEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 106. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 107. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 108. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 109. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 114. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 115. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 116. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 117. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 118. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 119. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 120. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 121. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 132. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 133. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 136. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 203. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 204. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 205. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 206. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 207. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 214. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 215. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 216. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 217. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 218. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 219. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 220. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 221. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 226. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 227. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 230. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 231. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 232. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 233. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 234. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 251. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 252. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 253. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 254. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 255. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 260. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 261. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 262. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 263. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 264. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 265. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 266. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 267. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 268. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 269. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 270. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 271. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 274. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 275. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 276. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 277. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 278. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 279. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 280. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 281. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 282. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SOURCE, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HEMATOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY PRIMARY IMMUNE DEFIC

Samples

Loading
LOADING...

Companies Mentioned

  • CSL Behring
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • Biotest AG
  • LFB S.A.
  • Bio Products Laboratory Limited
  • GC Pharma Co., Ltd.
  • Shanghai RAAS Blood Products Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 21.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 38.72 Billion
Compound Annual Growth Rate12.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Intravenous Immunoglobulin Market by End User (Home Care, Hospital, Specialty Clinic), Product Type (High Purity Immunoglobulin, Normal Immunoglobulin), Patient Type, Distribution Channel, Indication - Global Forecast 2025-2030 - Product Image

Intravenous Immunoglobulin Market by End User (Home Care, Hospital, Specialty Clinic), Product Type (High Purity Immunoglobulin, Normal Immunoglobulin), Patient Type, Distribution Channel, Indication - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Subcutaneous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), End User (Clinic, Home Healthcare, Hospital), Delivery Mode, Formulation, Strength - Global Forecast 2025-2030 - Product Image

Subcutaneous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), End User (Clinic, Home Healthcare, Hospital), Delivery Mode, Formulation, Strength - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033 - Product Image

Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033

  • Report
  • 200 Pages
  • Global
From
Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 153 Pages
  • Global
From
Intravenous Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033 - Product Image

Intravenous Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025-2033

  • Report
  • 175 Pages
  • Global
From

About the Immunoglobulin Market

The Immunoglobulin market is a segment of the Immune Disorders Drugs market, which focuses on treatments for conditions related to the immune system. Immunoglobulin (Ig) is a type of protein found in the blood that helps fight infection and disease. It is used to treat a variety of immune-related conditions, including autoimmune diseases, allergies, and infections. Immunoglobulin therapies are typically administered intravenously or subcutaneously, and can be used to replace or supplement the body's natural Ig production. The Immunoglobulin market is highly competitive, with a number of companies offering a range of products. These products vary in terms of dosage, delivery method, and cost. Companies in the market are focused on developing new therapies and improving existing ones, as well as expanding their product portfolios. Some of the major companies in the Immunoglobulin market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.